Non-Hodgkin s Lymphoma



Similar documents
Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

Lymphoma Diagnosis and Classification

Non-Hodgkin s lymphoma. Univ. Prof. Dr. Werner Linkesch Univ. Klinik Graz

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

Oncology Best Practice Documentation

Non-Hodgkin s lymphoma

Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham

Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data

Leukemias and Lymphomas: A primer

Malignant Lymphomas and Plasma Cell Myeloma

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on

Non Hodgkin Lymphoma:

Frequency of NHL Subtypes in Adults

Non-Hodgkin Lymphoma in Queensland An Overview 2012

Understanding Non-Hodgkin Lymphoma

Mantle Cell Lymphoma Understanding Your Treatment Options

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Cancer. 9p21.3 deletion. t(12;21) t(15;17)

Non-Hodgkin Lymphoma Richard Orlowski, MD

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

Immunohistochemical classification of malignant lymphomas

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA

Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA

Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital

Lymphoproliferative Disorders

Corporate Medical Policy

6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic

Non-Hodgkin Lymphoma

Lymphoma. Measurability of Quality Performance Indicators Version 2.0

Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone. Relative Frequency of B-cell NHL. Diffuse Large B-cell Lymphoma Definition

Cord blood Banking Transplant List for One USA Bank - StemCyte

Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed

MEDICAL COVERAGE POLICY

PERIPHERAL SMEARS: THE PRIMARY DIAGNOSTIC TOOL PART II IRMA PEREIRA, MT(ASCP)SH

Indolent Lymphomas. American Academy of Insurance Medicine 121 st Annual Meeting. Hilton LaJolla October 2012

Lymphoma: An Overview. Dr Louise Connell 05/03/2103

Dako provides cancer diagnostic products for leading reference laboratories, hospitals and other clinical and research settings.

Flow Cytometry A Guide for Data Analysis

-Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates

Audience Response Question? Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management. Presenter Disclosure Information

Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms

Cutaneous Lymphoma FAST FACTS

Because non-hodgkin's lymphoma is a more frequent and distinct disease I will discuss it in more details in this site study.

Rituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008

Challenging Diagnosis in Hematopathology

Locoregional & advanced esophagus or esophagogastric junction cancer

Audience Response Question?

Coding for Hematology

FDG-PET/CT in Lymphoma 3rd IPET Meeting, Vienna, October Ora Israel, MD Department of Nuclear Medicine Rambam Health Care Campus Haifa, Israel

Non-Hodgkin Lymphoma. Rick, non-hodgkin lymphoma survivor

Outline of lecture. Disclosures. Current Issues in Practical Hematopathology: Diagnosis of Bone Marrow Lymphomas

Guidelines on Diagnosis and Treatment of Malignant Lymphomas

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

ICD-10 CM/PCS Tip Sheets. Oncology

Part II: NCCN Practice Guidelines Narrative Summary PET and PET/CT

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma

Pediatric Oncology for Otolaryngologists

LCD for Erythrocyte Sedimentation Rate (ESR)

NEOPLASMS C00 D49. Presented by Jan Halloran CCS

Low grade non-hodgkin Lymphoma

ICD-10 FREQUENTLY ASKED QUESTIONS

CAR T cell therapy for lymphomas

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Subclassifying DLBCL. Diffuse Large B-Cell Lymphoma: Variants & Subtypes. Subclassifying DLBCL

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引

CHAPTER 2. Neoplasms (C00-D49) March MVP Health Care, Inc.

Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.

Interesting Case Series. Periorbital Richter Syndrome

Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma

Stem Cell Transplantation

Local Coverage Determination (LCD): Immunohistochemistry (L34369)

Transcription:

Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department

Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant lymphomas. There are many different subtypes, every few years the classification is updated. Today, morphology, immunophenotype, molecular, cytogenetics, and other techniques are used for diagnosis. Treatment generally depends on the aggressiveness of the disease (indolent, aggressive, or very aggressive) Current ICD-9-CM diagnosis code range 200.0_ 200.8_ and 202.0_ 202.9_

Behavior Indolent these lymphomas grow slowly. The majority of NHLs are considered indolent. Indolent lymphomas are generally considered incurable with chemotherapy and/or radiation therapy. Aggressive these lymphomas have a rapid growth pattern. This is the second most common form of NHL and are curable with chemotherapy. Very Aggressive these lymphomas grow very rapidly. They account for a small proportion of NHLs and can be treated with chemotherapy. Unless treated rapidly, these lymphomas can be life threatening.

WHO/REAL Classification of Lymphoid Neoplasms B-Cell Neoplasms Precursor B-cell neoplasm Precursor B-lymphoblastic leukemia/lymphoma (precursor B-acute lymphoblastic leukemia) Mature (peripheral) B-neoplasms B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma B-cell prolymphocytic leukemia Lymphoplasmacytic lymphoma Splenic marginal zone B-cell lymphoma (+ villous lymphocytes)* Hairy cell leukemia Plasma cell myeloma/plasmacytoma Extranodal marginal zone B-cell lymphoma of MALT type Nodal marginal zone B-cell lymphoma (+ monocytoid B cells)* Follicular lymphoma Mantle cell lymphoma Diffuse large B-cell lymphoma Mediastinal large B-cell lymphoma Primary effusion lymphoma Burkitt s lymphoma/burkitt cell leukemia T and NK-Cell Neoplasms Precursor T-cell neoplasm Precursor T-lymphoblastic leukemia/lymphoma (precursor T-acute lymphoblastic leukemia Formerly known as lymphoplasmacytoid lymphoma or immunocytoma II Entities formally grouped under the heading large granular lymphocyte leukemia of T- and NK-cell types * Provisional entities in the REAL classification Mature (peripheral) T neoplasms T-cell chronic lymphocytic leukemia / small lymphocytic lymphoma T-cell prolymphocytic leukemia T-cell granular lymphocytic leukemia II Aggressive NK leukemia Adult T-cell lymphoma/leukemia (HTLV-1+) Extranodal NK/T-cell lymphoma, nasal type # Enteropathy-like T-cell lymphoma** Hepatosplenic γδ T-cell lymphoma* Subcutaneous panniculitis-like T-cell lymphoma* Mycosis fungoides/sézary syndrome Anaplastic large cell lymphoma, T/null cell, primary cutaneous type Peripheral T-cell lymphoma, not otherwise characterized Angioimmunoblastic T-cell lymphoma Anaplastic large cell lymphoma, T/null cell, primary systemic type Hodgkin s Lymphoma (Hodgkin s Disease) Nodular lymphocyte predominance Hodgkin s lymphoma Classic Hodgkin s lymphoma Nodular sclerosis Hodgkin s lymphoma (grades 1 and 2) Lymphocyte-rich classic Hodgkin s lymphoma Mixed cellularity Hodgkin s lymphoma Lymphocyte depletion Hodgkin s lymphoma Not described in REAL classification Includes the so-called Burkitt-like lymphomas ** Formerly known as intestinal T-cell lymphoma # Formerly know as angiocentric lymphoma

Frequency of NHL Subtypes in Adults Peripheral T-cell (6%) Mantle cell (6%) Other subtypes with a frequency 2% (9%) Indolent (35%) Composite lymphomas (13%) Armitage et al. J Clin Oncol. 1998;16:2780 2795. Diffuse large B-cell (31%)

Marginal Zone Lymphoma Indolent Currently codes to 202.8_ Accounts for ~10% of all lymphomas Subcategories MALT (XRT?) Nodal Extra Nodal Splenic

Mantle Cell Lymphoma Aggressive Currently codes to 202.8_ Accounts for ~ 6% of all lymphomas Considered incurable with traditional RX Stem cell transplant is offered often as front-line consolidation treatment in younger patients

Primary CNS Lymphoma Aggressive Currently codes to 202.8_ Accounts for ~ 1-2% of all lymphomas Different chemotherapy treatments Often requires radiation to the brain:» Brain dysfunction in younger patients» Dementia in older patients

Aggressive Anaplastic Large Cell Lymphoma (ALCL) Currently codes to 202.8_ Accounts for ~ 2% of all lymphomas Two groups: ALCL ALK-1+ better prognosis, more common in younger patients and children ALCL ALK-1-negative : as bad as any other T-cell lymphoma

Peripheral T-cell Lymphoma Aggressive Currently codes to 202.8_ Accounts for ~ 7% of all lymphomas Worse prognosis, often associated with extranodal presentation Often requiring salvage treatment and transplant

Large Cell Lymphoma Very Aggressive Currently codes to 200.0_ Accounts for ~ 31% of all lymphomas

Other Recommendations Changes to terminology Changes in disease process

Questions?